Avadel Pharmaceuticals (AVDL) Debt to Equity (2016 - 2022)
Historic Debt to Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to -$10.95.
- Avadel Pharmaceuticals' Debt to Equity fell 86270.6% to -$10.95 in Q3 2022 from the same period last year, while for Sep 2022 it was -$10.95, marking a year-over-year decrease of 86270.6%. This contributed to the annual value of $1.82 for FY2021, which is 13033.26% up from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Debt to Equity is -$10.95, which was down 86270.6% from -$40.31 recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Debt to Equity registered a high of $45.03 during Q4 2018, and its lowest value of -$40.31 during Q2 2022.
- In the last 5 years, Avadel Pharmaceuticals' Debt to Equity had a median value of $0.74 in 2020 and averaged -$0.47.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Debt to Equity soared by 1124789.81% in 2021, and later crashed by 348011.7% in 2022.
- Avadel Pharmaceuticals' Debt to Equity (Quarter) stood at $45.03 in 2018, then tumbled by 109.68% to -$4.36 in 2019, then skyrocketed by 118.13% to $0.79 in 2020, then surged by 130.33% to $1.82 in 2021, then crashed by 701.74% to -$10.95 in 2022.
- Its Debt to Equity was -$10.95 in Q3 2022, compared to -$40.31 in Q2 2022 and $2.58 in Q1 2022.